Objective To assess the effect of 4 years' growth hormone (GH) replacement on glucose homeostasis and evaluate factors affecting glycosylated haemoglobin (HbA 1c ) in adults with growth hormone deficiency (GHD 
Introduction
Growth hormone (GH) plays an important role in regulating glucose homeostasis, and impaired glucose homeostasis and increased risk for diabetes have been reported in association with both GH insufficiency and GH excess. [1] [2] [3] In addition to impaired quality of life, reduced physical activity, decreased bone mineral density and adverse changes in body composition notably increased visceral fat mass, and growth hormone deficiency (GHD) in adults is characterized by an adverse metabolic profile and elevated cardiovascular risk markers. 4 Furthermore, risk factors associated with diabetes in the general population, 5 as a family history of diabetes mellitus or compromised beta-cell function and high body mass index (BMI), have been proposed to increase the risk for adverse changes in carbohydrate metabolism during GH replacement in patients with GHD.
an almost four-to fivefold increase in the incidence of diabetes mellitus. 7 A similar increased risk has been reported in patients with metabolic syndrome and GHD, 8 due in part to the concomitant visceral adiposity. 9 Because GHD in adults is associated with disturbances of carbohydrate metabolism, 9 special attention has been paid to changes in glucose, glycosylated haemoglobin (HbA 1c ) levels and other parameters of glucose metabolism during GH replacement. It has been speculated that the favourable effects of GH replacement on body composition, including reduced adiposity, may counteract the potential adverse effects of GH replacement, resulting in insulin resistance and hyperglycaemia. 10 Although a transient increase in fasting plasma glucose (FPG) was reported in some studies after initiating GH replacement, 10, 11 others report equivocal effects of GH replacement on insulin sensitivity. 12, 13 However, these studies involved small patient numbers and a higher GH dose than currently recommended. Indeed, low-dose (0Á1 mg/day) GH replacement enhanced insulin sensitivity during a 12-month period, but a standard dose (0Á5 mg/ day) did not. 14 Duration of treatment may represent a confounding factor with a deterioration of glucose metabolism during the initial phase, which may be followed by improved glycaemia and insulin levels as body composition improves with long-term GH replacement. 15, 16 Furthermore, previous findings from observational studies are inconsistent, with both increased risk 1 and no increased risk reported. 15, [17] [18] [19] No association between diabetes incidence and GH dose has been described. 1, 18 While these conflicting data may be due in part to different study methods and design, 12, 13, 20 the effects of GH replacement on glucose homeostasis in adults with GHD remain unclear. This study evaluates the effect of 4 years' continuous GH replacement on HbA 1c , FPG and parameters of cardiovascular risk in nondiabetic adults with GHD receiving GH replacement enrolled in the observational NordiNet â International Outcome Study (IOS) (Novo Nordisk A/S, Bagsvaerd, Denmark).
Patients and methods

Patients
Nondiabetic patients who fulfilled the criteria for the diagnosis of adult GHD, 21 aged ≥20 years at GH treatment start (adultonset GHD), enrolled in NordiNet â IOS with at least 4 years' GH replacement with Norditropin â , and HbA 1c values at baseline and 4 years were eligible for inclusion in the analyses (n = 272). Patients with a pre-existing diagnosis of diabetes or receiving antidiabetic treatment at the start of GH replacement [n = 19; type 1 diabetes, n = 3 (female, n = 2; age 37-57 years); type 2 diabetes, n = 16 [female, n = 6; age 22-68 years)] or HbA 1c values above 6Á5% at both baseline and at 4-year followup [n = 8; (female, n = 8; age 27-74 years)] were excluded, leaving a total of 245 eligible patients. All patients provided written informed consent prior to enrolment in NordiNet â IOS. NordiNet â IOS is conducted in accordance with the Declaration of Helsinki, 22 was approved by the local institutional ethics committee/institutional review board and the local regulatory authorities at each study centre and data privacy agencies as required, and complies with Good Pharmacoepidemiology Practice guidelines. The study registration number is NCT00960128 (www.clinicaltrials.gov).
Study design
The 26 and/or when reported as an additional diagnosis and/or when antidiabetic medication was prescribed. Furthermore, the glycaemic status of each patient was assessed by HbA 1c levels as normal (<5Á7%), impaired glucose tolerance (5Á7-6Á4%) or diabetes (≥6Á5%).
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A paired t-test was used to analyse the individual DHbA 1c to year of treatment. A chi-square test was applied to test the association between GH dose during the 4th year of treatment (low, ≤0Á2 mg/day; standard >0Á2 mg/day) and a clinically relevant DHbA 1c (≥0Á3% increase or decrease) or unchanged HbA 1c after 4 years of GH treatment. The distinction between 'low' and 'standard' dose of GH was set at 0Á2 mg/day, based on the authors' clinical experience.
The model used for DHbA 1c was also used to analyse the change in FPG from baseline (DFPG) to year of treatment. If FPG values were unavailable, blood glucose values were converted to FPG. 27 A multiple regression model, including gender, age at GH treatment start, average GH dose and treatment duration (year), was used to analyse change from baseline in secondary outcome parameters, IGF-SDS, waist circumference and lipids. The analysis of HDL cholesterol, LDL cholesterol, total cholesterol and triglycerides was also corrected for lipid-lowering therapy. The baseline level of each outcome parameter was included in the model.
The proportions of patients meeting the criteria for metabolic syndrome were calculated at baseline and 4 years. The metabolic syndrome criteria were defined as presence of at least three of five risk factors: triglycerides ≥1Á7 mmol/l or on drug treatment for elevated triglycerides; HDL cholesterol <1Á03 mmol/l (male)/ <1Á30 mmol/l (female) or on drug treatment for reduced HDL cholesterol; waist circumference ≥102 cm (male)/≥88 cm (female); systolic blood pressure ≥130 mmHg or diastolic blood pressure ≥85 mmHg or antihypertensive therapy in a patient with a history of hypertension; and elevated fasting glucose ≥5Á6 mmol/l or on drug treatment for elevated glucose. 6 
Results
Baseline characteristics, GH dose and IGF-I SDS
Baseline characteristics and 4-year data for the 245 (43% female) patients included in the analysis are presented in Table 1 . Median (range) age at treatment start was 50 (21-85) years and median GH dose was 0Á17 (0Á05-1Á20) mg/day. During year 4, most (72%; 177/245) patients received a standard GH dose (>0Á2 mg/day). Median BMI of 28 (17-55) kg/m 2 indicated that most patients were overweight (BMI 25-30 kg/m 2 ) at baseline; 10 patients had obesity (BMI ≥30 kg/m 2 ) at treatment start. Reported medical conditions at baseline with nonpituitary pathology are shown in Table S1 (Supporting Information) for all patients and in Table 3 for patients with cardiovascular events within the 4-year GH treatment period. At 4 years of GH replacement, the mean GH dose was increased by 68% from baseline (Table 1 ). In the total cohort, mean (SD) IGF-I SDS increased from <0 at baseline to >0 after 4 years of GH replacement (Table 1) . Gender (estimated effect (EE; female), À0Á3215; P < 0Á0001] and age at treatment start (EE, 0Á009434; P = 0Á0009), but not mean dose at relevant year (EE, 0Á1751; P = NS), had a significant impact on the change in IGF-I SDS from baseline to year 4, with older patients experiencing a greater mean change in IGF-I SDS than younger patients.
Concomitant medications
Overall, 114 (46Á5%) patients were prescribed glucocorticoids [mean (range) dose 19Á3 (5Á0-40Á3) mg/day (n = 80)], with most (91Á2%) starting treatment prior to or on starting GH replacement. Lipid-lowering (statin) treatment was prescribed for nine patients, of whom seven started treatment after starting GH replacement.
Glucose homeostasis
Patients developing diabetes during the 4-year follow-up period. Overall, seven patients developed diabetes during the first 4 years of GH replacement (Table 1) . These patients tended to be older, receiving a lower GH dose and had a greater BMI at baseline compared with the total cohort, and all but one received concomitant treatment with glucocorticoids. At baseline, three of these patients had normal HbA 1c and four had impaired glucose Table 2) . BMI (P = 0Á0008) also had a significant impact on DHbA 1c ; a significantly greater increase in HbA 1c was shown in patients with obesity (BMI ≥30 kg/m 2 ) than in patients with normal BMI (<25 kg/m 2 ; EE, 0Á1280; P = 0Á0005), but DHbA 1c was similar between patients with normal BMI and those with overweight (Table 2) . No significant effect of gender, GH dose or treatment with glucocorticoids on DHbA 1c was observed. Antidiabetic treatment did not have a statistically significant influence on the results due to the low number of patients with reported antidiabetic treatment (n = 2). The model adjustment for baseline HbA 1c was significant (P < 0Á0001). Overall, >50% of patients in each GH dose group experienced no change in HbA 1c status during 4 years of GH replacement and similar proportions of patients in both dose groups experienced a decrease in HbA 1c , while proportionally more patients in the low-versus the standard-dose group exhibited an increase in HbA 1c (Fig. 1) ; however, no significant association was found between GH dose group and clinically relevant DHbA 1c at year 4 (P = 0Á2419).
Fasting plasma glucose. A small increase in mean FPG (n = 187) levels from baseline to 4 years was observed (Table 1 ). Age at treatment start (EE, 0Á0066; P = 0Á0106) and GH dose (EE, À0Á4475; P = 0Á0267) had a significant effect on ΔFPG from baseline to 4 years; older patients at baseline had a greater increase in FPG than younger patients, and patients with higher GH doses had a greater reduction in FPG. No effect of BMI, gender or glucocorticoid treatment was observed.
Glycaemic health status according to HbA 1c . At baseline, the majority of patients (78Á4%, n = 192) had normal HbA 1c levels, 51 (20Á8%) patients had impaired glucose tolerance and two (0Á8%) patients had HbA 1c ≥6Á5%. The majority (84Á9%) of those with normal baseline HbA 1c remained within this range at 4 years, 27 (14%) progressed to impaired glucose tolerance and two (1Á1%) had HbA 1c levels ≥6Á5% at 4 years. Although 28 (54Á9%) patients with impaired glucose tolerance at baseline remained in this category at 4 years, 19 (37Á3%) patients in this group improved to normal HbA 1c levels and four (7Á8%) progressed to HbA 1c levels ≥6Á5%. The two patients with HbA 1c ≥6Á5% at baseline improved to normal or impaired glucose tolerance at 4 years.
Metabolic syndrome index. Among the 125 (51%) patients with data on the metabolic syndrome at baseline, 36% (45/125) of patients fulfilled the criteria for metabolic syndrome at baseline and 40% (40/101) fulfilled these criteria at 4 years.
Cardiovascular risk markers
Adiposity (waist circumference). After 4 years' GH replacement, mean (SD) waist circumference was similar to baseline [baseline, 99Á9 (14Á2) cm (n = 140); 4 years, 99Á3 (15Á0) cm, (n = 137); mean change from baseline, À0Á69 (6Á2) cm (n = 108)]; however, a higher GH dose was associated with a greater reduction in waist circumference (EE, À5Á2418; P = 0Á0002). No effect of gender or age at treatment start was observed. observed [mean (SD) change from baseline, 0Á02 (0Á33) mmol/l (n = 173)]. Age at treatment start (EE, 0Á0018; P = 0Á0276) and gender (EE, 0Á0711; P = 0Á0021), but not antilipid treatment, had a significant impact on the change in HDL cholesterol from baseline, with older patients having a greater increase in HDL cholesterol than younger patients.
Low-density lipoprotein cholesterol. Mean (SD) LDL cholesterol levels decreased from 3Á57 (1Á13) mmol/l (n = 178) at baseline to 3Á36 (0Á93) mmol/l (n = 164) at 4 years. Of the parameters tested, only antilipid therapy had a significant effect on change in LDL cholesterol from baseline (EE, À0Á4417; P = 0Á0092).
Total cholesterol. Mean (SD) total cholesterol levels decreased from 5Á79 (1Á27) mmol/l (n = 217) at baseline to 5Á42 (1Á09) mmol/l (n = 192) at 4 years [mean change from baseline À0Á38 (1Á20) mmol/l (n = 175)]. Gender (EE, 0Á3341; P < 0Á0001) and antilipid treatment (EE, À0Á5829; P = 0Á0006) had a significant impact on the change from baseline; neither age at treatment start nor GH dose had an observed effect.
Triglycerides. Mean (SD) triglyceride levels increased slightly from baseline [1Á73 (1Á21) mmol/l (n = 119)] at 1 year [1Á93 (1Á30) mmol/l (n = 79)] and then decreased during subsequent years [2 years, 1Á92 (1Á20) mmol/l (n = 96); 3 years, 1Á92 (1Á33) mmol/l (n = 73); 4 years, 1Á89 (1Á20) mmol/l (n = 75)]; overall mean (SD) change from baseline was À0Á01 (1Á09) mmol/l (n = 50). Age at baseline had a significant impact on the change in triglycerides; patients who were older at baseline had a greater reduction in triglyceride levels during the 4-year period (EE, À0Á0076; P = 0Á0422) than younger patients.
Cardiovascular events reported during the follow-up period. Six patients [2Á4%; female n = 4; median age at event, 66Á5 (range 40-75) years] experienced seven cardiovascular events during the 4-year period after starting GH replacement [median duration of treatment, 1Á1 (0Á4-4Á2) years; Table 3 ]. Obesity, reported in three patients at baseline, and weight gain in one patient after starting GH, may have been predisposing factors. The most common event, hypertension, was reported in four patients; stroke was reported in two patients (one of whom later also developed hypertension), and ischaemic heart disease was reported in one elderly male patient (age, 74Á5 years) approximately 1 year after starting GH replacement.
Discussion
This international study with data from real-life clinical practice demonstrates that 4 years of GH replacement therapy in nondiabetic patients with adult-onset GHD does not adversely impact glucose metabolism in most patients. Mean HbA 1c remained at the same levels from baseline and a small increase in FPG was observed. Very few patients showed any deterioration in glycaemic health status; indeed, more than one-third of patients with impaired glucose tolerance at baseline showed improvement to normal HbA 1c levels at 4 years. Moreover, the proportion of patients with metabolic syndrome was similar at baseline and following 4 years of GH replacement.
Notwithstanding the increased risk of progression to diabetes associated with age 29 and presence of GHD, 3 19 patients in our cohort of 245 patients improved from impaired glucose tolerance to normal glucose HbA 1c levels, and only seven patients developed diabetes during 4 years of GH treatment. Two other postmarketing surveillance databases have reported on diabetes during GH treatment. Although an increased risk for diabetes was reported in 5143 patients in KIMS followed for a mean of 3Á9 (range 0Á01-13) years compared with a reference population, 1 a report from HypoCCS concluded there was no significant increase in the incidence of diabetes compared with several reference populations, among 6672 patients from the USA and Europe followed for a mean of 4Á1 years. 18 Using a proportional hazard model, age and BMI were shown to be associated with increased risk for diabetes. In our study, an increase in triglyceride levels from baseline was observed at 1 year, after which a small decrease was observed so that at 4 years mean triglyceride levels were unchanged from baseline. Although insulin sensitivity was not measured directly, as fasting insulin levels are not routinely assessed in clinical practice, this suggests that any decrease in insulin sensitivity during GH replacement may be transient. In an 18-month randomized placebo-controlled trial involving 40 men with GHD, Sesmilo et al. reported short-term increases in glucose and insulin levels as well as the glucose/insulin ratio of which only the elevated glucose levels were sustained, together with transient reductions in lipids. 30 Moreover, long-term GH replacement in adults may even help to slow the age-related decline in insulin sensitivity. 12 Some evidence suggests that low-dose GH may have positive effects on insulin sensitivity and FPG independently of GHinduced improvements in body composition.
14 In the present study, change in HbA 1c was independent of GH dose. Indeed, a similar proportion of patients on low-and standard-dose GH experienced a decrease in HbA 1c from baseline to 4 years. Although a mean decrease in waist circumference was observed in the standard-dose group versus a small increase in the lowdose group, it is not possible to draw an inference regarding the potential benefits of low-dose versus standard-dose GH replacement because the focus of this study was to assess the overall effects of GH replacement on glucose homeostasis. The classical risk factors associated with the development of type 2 diabetes in the general population are typically the same characteristics observed in untreated patients with GHD. 1, 2, 18 In our study, although the majority of patients with normal baseline HbA 1c levels maintained their normal glycaemic status, those with obesity had a greater increase in HbA 1c than those with a normal BMI. Together, these findings suggest that GH replacement does not adversely impact glucose metabolism in adults with GHD without additional risk factors. Monitoring glucose parameters is advisable in all patients taking GH replacement, especially in those with additional risk factors for developing hyperglycaemia. Use of glucocorticoids may influence the development of diabetes. 31 Even though we found no effect of glucocorticoids on HbA 1c or FPG, the lack of clinical details of glucocorticoid therapy, including glucocorticoid type, dose, changes in dose and time of initiation for a proportion of patients, represents a limitation in our study. In the present study, cardiovascular events were reported in 2Á4% (6/245) of patients during GH replacement, with hypertension reported in four patients. Changes in HDL cholesterol, LDL cholesterol and total cholesterol during GH replacement were also observed; treatment with statins had a significant impact on the observed changes in LDL cholesterol and total cholesterol that should be considered when interpreting these data. It is also noteworthy that adverse cardiovascular outcomes are more prevalent in nondiabetic, GH-treated adult patients with GHD and conventional risk factors than in those with no known risk factors, 32 and may also be exacerbated by glucocorticoid therapy started following initiation of GH replacement 33 ; in our study, 46% of patients received glucocorticoid replacement.
A considerable strength of this study is that it reports longitudinal changes in HbA 1c levels in GH-treated adult patients with GHD over a period of 4 years in a real-world multinational setting. The limitations of this study, as with all observational studies, include the lack of control group and selection and information biases introduced by the selection of patients, the variety of methods used to analyse blood samples and different treatment practices across countries.
Conclusions
These data collected in a real-life clinical setting demonstrate that 4 years of growth hormone replacement therapy in adults with growth hormone deficiency had no adverse impact on glucose homeostasis in the majority of patients. Monitoring glucose parameters is advisable in all patients taking growth hormone replacement, perhaps more frequently in those at higher risk of developing hyperglycaemia. 
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